loader image


Across Trinity College Dublin, the Wrocław University of Environmental and Life Sciences (Poland) and the University of Galway in-vitro laboratory studies confirmed the efficacy of BEEMAR™ against a complex series of viral pathogens. Critically, the very high levels of anti-virucidal activity have been achieved with no reported cytotoxicity, validating not only the efficacy of the formulation, but also its safety. Virucidal efficacy of ≥ 99. 99% has been achieved across multiple in-vitro studies at multiple academic sites for each of the viruses listed below.

  • Herpes Simplex (HSV-1)
  • Equine Herpes Virus (EHV-1)
  • Polio Virus (Picornaviridae)
  • Adenovirus type 1 (Adenoviridae)
  • Coronavirus OC43·Vaccinia poxivirus (smallpox)
  • Influenza

In-Vitro Trials: Malaria

In Q2 2022 The Noguchi Memorial Institute for Medical Research, Ghana embarked on a twin-track approach to explore the efficacy of the BEEMAR™ platform in the fight against Malaria. Cell based assays demonstrated a clear chemo suppression of Plasmodium parasites when treated with BEEMAR™

Distinct forms and life stages of the malaria parasites exist within red blood cells upon infection. These different parasite forms respond differently to different antimalarial drugs due to subtle differences in their biology. Using the sybr green 1 assay and the ring stage survival assay researchers at NMIMR found a significant suppression of the parasites under cell culture.

These results helped secure ethical approval for a pre-clinical study. In this study the BEEMAR™ formulation compared very favourably against the control combination-pharmaceutical drug. Critically, not only was the BEEMAR™ formulation highly effective, it displayed no signs of cytotoxicity.

Join the Movement

Be the first to know what’s happening